ISRCTN15768745暂停Unknown
A cluster-randomised 12-month, parallel arm, superiority trial of a multifaceted intervention to promote child VaccInation and linKage to sociAl protection Schemes (VIKAS) versus usual services on vaccination uptake among children 12 - 23 months
适应症
试验速览
- 阶段
- Unknown
- 状态
- 暂停
- 入组人数
- 7,810
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Communities:
- •1.1. Located in a catchment area of a health sub-centre assigned to the intervention group,
- •1.2. Designated as possible missed community (low immunisation area), and
- •1.3. Consent is received from community gatekeepers (local elected officials with territorial responsibility, such as the Pradhan (mayor)).
- •2. All adult (>18 years of age) participants in communities selected to receive the intervention will be eligible to participate
- •3. All frontline health workers in the intervention group with territorial responsibility for a community selected to receive the interventions will be included in the field interventions.
- •4. Participants in the baseline and end line cross-sectional household surveys are primary caregivers (usually mothers) and other adult (over age 18 years ) family members of immunisation-age (0 to 23 months) children. Participants are eligible for inclusion in the household surveys if they reside in a study cluster (rural health sub-centre) catchment area and in an immunisation microplan area designated as a possible low immunisation area, and provide written informed consent. We will exclude those not able to understand and speak Hindi or Urdu.
排除标准
- •1. Participation in Interventions: None.
- •2. Participation in data collection: We will exclude those not able to understand and speak Hindi or Urdu. Based on our experience, in this district, this criterion would result in exclusion of less than 1% of respondents.
研究者
相似试验
进行中(未招募)
1 期
Comparison of Ozurdex versus Lucentis in the treatment of BranchRetinal Vein Occlusion.Macula oedema secondary to branch retinal vein occlusion.MedDRA version: 14.0Level: PTClassification code 10025415Term: Macular oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: PTClassification code 10038907Term: Retinal vein occlusionSystem Organ Class: 10015919 - Eye disordersEUCTR2010-023900-29-ESAllergan Pharmaceuticals Ireland307
进行中(未招募)
1 期
A 12-Month, Multicentre, Randomised, Parallel Group Study to Comparethe Efficacy and Safety of Ozurdex Versus Lucentis in Patients withBranch Retinal Vein OcclusionMacula oedema secondary to branch retinal vein occlusionMedDRA version: 14.1Level: PTClassification code 10025415Term: Macular oedemaSystem Organ Class: 10015919 - Eye disordersEUCTR2010-023900-29-ITALLERGAN PHARMACEUTICALS IRELAND307
进行中(未招募)
1 期
Comparison of Ozurdex versus Lucentis in the treatment of Branch Retinal Vein OcclusioEUCTR2010-023900-29-GBAllergan Pharmaceuticals Ireland307
进行中(未招募)
不适用
Comparison of Ozurdex versus Lucentis in the treatment of Branch Retinal Vein OcclusioEUCTR2010-023900-29-DEAllergan Pharmaceuticals Ireland308
进行中(未招募)
1 期
Study to assess the effect of AZD3241 in Multiple System AtrophyMultiple system atrophy (MSA)MedDRA version: 18.1Level: PTClassification code 10064060Term: Multiple system atrophySystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-004902-13-SEAstraZeneca AB64
